Date: 2016-04-19
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, USA
Company: Transgene (France)
Product: new generation oncolytic viral immunotherapy product candidate
Action
mechanism: immunotherapy product/oncolytic virus/gene therapy/oncolytic immunotherapy/immune checkpoint inhibitor.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 19, 2016, Transgene announced that preclinical data on an internally developed, new generation oncolytic viral immunotherapy product candidate was presented at the Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, USA. (The AACR poster is entitled 'Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition'.) At the AACR meeting, Transgene reported pre-clinical results with three oncolytic vaccinia viruses, each containing a different form of a PD-1 blocker (VV-PD-1): a full monoclonal antibody (mAb), an antigen-binding fragment (Fab) or a single-chain variable fragment (scFv). The data showed that all three versions of the VV-PD-1 expression products displayed (i) a perfect biochemical integrity and folding, (ii) were fully functional, and (iii) had equivalent biological activity to the corresponding anti PD-1 reference mAb. Furthermore, the biodistribution profile obtained for VV-PD-1 demonstrated a higher concentration and prolonged action of the anti PD-1 in the tumor, resulting in an improved tumor/serum ratio. Finally, the therapeutic activity was assessed in a pre-clinical model for sarcoma, showing similar activity for VV-PD1 to the combination of VV and anti-PD1 mAb, both in terms of tumor growth prevention and survival, but was considerably higher than any of the single products. These results support advancing the development of these next generation oncolytic vaccinia viruses armed with antibodies, and more generally, with other types of immune-active functions.
